New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors

Molecular Therapy

Volumn 12, Issue 6, 2005, Pages 1168-1175

  Garanger, Elisabeth ^a,b   Boturyn, Didier ^b   Jin, Zhaohui ^a   Dumy, Pascal ^b   Favrot, Marie Christine ^a   Coll, Jean Luc ^a  

^a INSTITUT ALBERT BONNIOT   (France)

^b UNIVERSITÉ JOSEPH FOURIER   (France)

Author keywords

Angiogenesis; Integrin; Nonviral drug delivery; Optical imaging

Indexed keywords

CYCLOPEPTIDE; INTEGRIN; LIGAND; VITRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL ADHESION; CLONING VECTOR; CONTROLLED STUDY; COVALENT BOND; DISSEMINATED CANCER; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG TARGETING; ENDOCYTOSIS; EXPERIMENTAL ANIMAL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOLECULAR CLONING; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; STEREOSPECIFICITY; STRUCTURE ANALYSIS; SUBCUTANEOUS TISSUE TUMOR;

ANIMALIA; MUS MUSCULUS;

EID: 28444471558     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.06.095     Document Type: Article

References (24)

1. D. Boturyn J.L. Coll E. Garanger M.C. Favrot and P. Dumy Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis J. Am. Chem. Soc. 126 2004 5730-5739
2. R.O. Hynes Integrins: Versatility, modulation, and signaling in cell adhesion Cell 69 1992 11-25
3. F.G. Giancotti and E. Ruoslahti Integrin signaling Science 285 1999 1028-1032
4. M.J. Humphries Integrin structure Biochem. Soc. Trans. 28 2000 311-339
5. P.C. Brooks R.A. Clark and D.A. Cheresh Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264 1994 569-571
6. A. Giannis and F. Rübsam Integrin antagonists and other low molecular weight compounds as inhibitors of angiogenesis: New drugs in cancer therapy Angew. Chem. Int. Ed. Engl. 36 1997 588-590
7. R. Haubner D. Finsinger and H. Kessler Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alpha v beta 3 integrin for a new cancer therapy Angew. Chem. Int. Ed. Engl. 36 1997 1374-1389
8. X. Chen P.S. Conti and R.A. Moats In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts Cancer Res. 64 2004 8009-8014
9. M. Aumailley et al. Arg-Gly-Asp constrained within cyclic pentapeptides: strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 FEBS Lett. 291 1991 50-54
10. R. Allman P. Cowburn and M. Mason In vitro and in vivo effects of a cyclic peptide with affinity for the alpha v beta 3 integrin in human melanoma cells Eur. J. Cancer 36 2000 410-422
11. M. Pfaff et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins J. Biol. Chem. 269 1994 20233-20238
12. M.A. Dechantsreiter et al. N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists J. Med. Chem. 42 1999 3033-3040
13. A.J. Schraa et al. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting J. Controlled Release 83 2002 241-251
14. A.J. Schraa et al. Targeting of RGD-modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study Int. J. Cancer 102 2002 469-475
15. S. Castel et al. RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways Lab. Invest. 81 2001 1615-1626
16. X. Chen J. Wang B. Fu and L. Yu RGD-containing peptides trigger apoptosis in glomerular mesangial cells of adult human kidneys Biochem. Biophys. Res. Commun. 234 1997 594-599
17. C.D. Buckley et al. RGD peptides induce apoptosis by direct caspase-3 activation Nature 397 1999 534-539
18. K. Meerovitch et al. A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen Vasc. Pharmacol. 40 2003 77-89
19. R. Haubner et al. Radiolabelled alpha(v)beta3 integrin antagonists: A new class of tracers for tumor targeting J. Nucl. Med. 40 1999 1061-1071
20. R. Haubner et al. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics J. Nucl. Med. 42 2001 326-336
21. 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res. 61 2001 1781-1785
22. 64Cu-labeled dimeric RGD peptides Mol. Imaging Biol. 6 2004 350-359
23. M.L. Janssen et al. Tumor targeting with radiolabelled alpha v beta 3 integrin binding peptides in a nude mouse model Cancer Res. 62 2002 6146-6151
24. P.L. Lollini et al. Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer interferon-gamma in the same cell: Efficient MHC expression and inhibition of tumour and metastasis growth Hum. Gene Ther. 6 1995 743-752